Journal: bioRxiv
Article Title: Genomic stress drives activation of interferon signaling and innate immune pathways during SMA Type II myoblasts differentiation
doi: 10.64898/2025.12.23.696216
Figure Lengend Snippet: A) Scheme of treatment of control myoblasts with cGAS agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.
Article Snippet: Myoblasts were transfected at 80% confluence with 1mg/mL cGAS activator (2’3’-cGAMP Invivogen #tlrl-nacga23-02) using Lipofectamine 2000 (Invitrogen) in differentiation media according to the manufacturer’s instructions.
Techniques: Control, Expressing, Enzyme-linked Immunosorbent Assay